Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anti-influenza immune plasma
- Development stage
- Phase 3
- Lead developer
- National Institute of Allergy and Infectious Diseases
- Administration
- Intravenous
01
Overview
Anti-influenza immune plasma is a blood product containing high levels of antibodies against influenza viruses. It is derived from donors who have high antibody titers to influenza, typically measured by hemagglutination inhibition (HAI) antibody titers. This therapeutic approach has been investigated as a potential treatment for severe influenza infections, particularly for hospitalized patients with influenza A or B. The plasma is administered intravenously and is intended to provide passive immunity to help combat the viral infection.
- Other names
- high-titre anti-influenza plasmaimmune plasma
02
Targets
HA (Hemagglutinin)
Beyond the preview
Go deeper on anti-influenza immune plasma.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anti-influenza immune plasma.